Glioma, Malignant Clinical Trial
Official title:
Glioma: BIOMOLECULAR Aspects From Tissue to Radiomics
Main limitations in Glioma studies are due to the wide heterogeneity and genetic instability of the tumor and to the fact that the molecular informations are static, i.e. obtained on the tumor at its onset. Instead, spontaneous or therapy-induced variations are difficult to evaluate and they would need further sampling of the tumor throughout the clinical history. Currently these data are more and more routinely used not only for diagnostics but also in the clinical management of the patient. Furthermore, microenvironment study is becoming increasingly important. It is also important correlate morpho-functional pathway and brain Magnetic Resonance. Therefore, the main goal of the study is to correlate the data obtained with morphological (site, signal intensity, margins, behavior after contrast medium infusion, mismatch between T2 and FLAIR sequences) and non-morphological MR imaging through a radiomic approach and Diffusion and Perfusion study, with molecular data relating to the IDH mutation, MGMT gene promoter methylation, 1p/19q co-deletion and EGFRvIII expression. Furthermore, it is proposed to carry out a correlation between the radiological data and the mutations found in the NGS panel.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557240 -
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
|
N/A | |
| Recruiting |
NCT05474573 -
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
|
N/A | |
| Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
| Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
| Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
| Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
| Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
| Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
| Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
| Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
| Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
| Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
| Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
| Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
| Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A | |
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 |